Objective:

To evaluate the effectiveness and safety of the reduced-dose combination of daratumumab, bortezomib, and dexamethasone (DVd-lite) in patients with newly diagnosed monoclonal gammopathy of renal significance (MGRS).

Approach:

Key Findings:

• Thestudyreportedahematologicaloverallresponserate(ORR)of80%andarenalORRof90%.Completeresponseratesinbothhematologyandrenalcategorieswerefoundtobe60%.Notably,onlyonepatientexperiencedagrade3treatment-relatedadverseevent.

Interpretation:

The DVd-lite regimen was well-tolerated and demonstrated promising efficacy in patients with newly diagnosed MGRS.

Limitations:

• Small sample size of ten patients.
• Short median observation period of 13.1 months.

Conclusion:

The findings suggest that the DVd-lite regimen may be an effective treatment for MGRS, indicating a need for further research.

Sources:

• Clinical Trial Registration
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.